Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis
Muscle & Nerve · 2025
DOI: 10.1002/mus.28422 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Weiwei Duan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hunan Provincial Rehabilitation Hospital, Changsha, P.R. China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Plasma Exchange, Leukapheresis. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Health Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
Introduction/Aims Lymphoplasmapheresis (LPE) is an innovative therapy that integrates traditional plasma exchange (PE) with leukapheresis. PE is widely established as a standard treatment for myasthenia gravis (MG) crisis, but the therapeutic potential of LPE in myasthenic crisis (MC) remains unclear. Therefore, this study aimed to compare the efficacy of LPE versus PE in the management of MC.
Methods
This was a retrospective cohort study that included 86 MC patients who were treated with either LPE ( n = 47) or PE ( n = 39). Primary outcome indicators were total length of hospitalization, duration of mechanical ventilation (MV), and length of stay in the intensive care unit (ICU). Secondary outcome indicators included quantitative myasthenia gravis (QMG) scores at 1 and 2 months following the onset of the crisis.
Results
Both LPE and PE demonstrated good tolerance in the crisis treatment. Patients in the PE cohort received an average of 3.87 replacements, compared to 2.26 in the LPE cohort. Compared to PE, LPE was associated with significantly shorter durations of MV (8.50 ± 4.69 vs. 11.73 ± 4.61 days, p = 0.016) and ICU stay (11.88 ± 5.78 vs. 15.92 ± 5.54 days, p = 0.013). Functional outcomes were also better in the LPE cohort, as demonstrated by lower QMG scores at 1‐ and 2‐months post‐crisis ( p < 0.05). PE and LPE effectively decreased the levels of autoantibodies against acetylcholine receptors (AChR‐Ab) and inflammatory cytokines, with LPE exhibiting superior performance.
Discussion
In MC, LPE may be a better choice for treatment than traditional PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Hunan Provincial Rehabilitation Hospital, Changsha, P.R. China.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, P.R. China.
- Department of Rehabilitation Medicine, Hunan Provincial People's Hospital, Hunan Normal University, Changsha, P.R. China.
- Department of Neurology, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, P.R. China.
- Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, P.R. China.
- Department of Blood Transfusion, Xiangya Hospital, Central South University, Changsha, P.R. China.
ORCID-Profile: Kaiyue Zhang, Huan Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Health Research Project of Hunan Provincial Health Commission
Zitieren
APA
Duan, W., Cai, H., Li, C., Ouyang, S., Yin, W., Zeng, Q., Jiang, F., Zhang, K., Chen, K., Zhou, Q., Li, B., & Yang, H. (2025). Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis. Muscle & Nerve. https://doi.org/10.1002/mus.28422
Vancouver
Duan W, Cai H, Li C, Ouyang S, Yin W, Zeng Q, et al. Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis. Muscle & Nerve. 2025. doi:10.1002/mus.28422
BibTeX
@article{Duan2025,
author = {Duan, Weiwei and Cai, Haobing and Li, Chen and Ouyang, Song and Yin, Weifan and Zeng, Qiuming and Jiang, Fei and Zhang, Kaiyue and Chen, Kangzhi and Zhou, Qian and Li, Bijuan and Yang, Huan},
title = {Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28422}
}
EUVIMED